[go: up one dir, main page]

ZA201409322B - Injectable antibiotic formulations and their methods of use - Google Patents

Injectable antibiotic formulations and their methods of use

Info

Publication number
ZA201409322B
ZA201409322B ZA2014/09322A ZA201409322A ZA201409322B ZA 201409322 B ZA201409322 B ZA 201409322B ZA 2014/09322 A ZA2014/09322 A ZA 2014/09322A ZA 201409322 A ZA201409322 A ZA 201409322A ZA 201409322 B ZA201409322 B ZA 201409322B
Authority
ZA
South Africa
Prior art keywords
methods
antibiotic formulations
injectable antibiotic
injectable
formulations
Prior art date
Application number
ZA2014/09322A
Other languages
English (en)
Inventor
Jain Rohit
George Tucker Ian
Al Alawi Fadil
Nanjan Karthigeyan
Bork Olaf
Original Assignee
Bayer New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49949085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201409322(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from NZ613138A external-priority patent/NZ613138B2/en
Application filed by Bayer New Zealand Ltd filed Critical Bayer New Zealand Ltd
Publication of ZA201409322B publication Critical patent/ZA201409322B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA2014/09322A 2012-07-17 2014-12-18 Injectable antibiotic formulations and their methods of use ZA201409322B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NZ60129912 2012-07-17
NZ61017513 2013-05-03
NZ613138A NZ613138B2 (en) 2013-07-12 Injectable antibiotic formulations and their methods of use
PCT/NZ2013/000123 WO2014014363A1 (en) 2012-07-17 2013-07-16 Injectable antibiotic formulations and their methods of use

Publications (1)

Publication Number Publication Date
ZA201409322B true ZA201409322B (en) 2015-12-23

Family

ID=49949085

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/09322A ZA201409322B (en) 2012-07-17 2014-12-18 Injectable antibiotic formulations and their methods of use

Country Status (30)

Country Link
US (1) US10376585B2 (ru)
EP (1) EP2874624B8 (ru)
JP (1) JP6189437B2 (ru)
KR (1) KR102113822B1 (ru)
CN (1) CN104470517B (ru)
AU (1) AU2013290826B2 (ru)
BR (1) BR112014031083B1 (ru)
CA (1) CA2875351C (ru)
CL (1) CL2014003423A1 (ru)
CO (1) CO7240359A2 (ru)
CR (1) CR20140550A (ru)
DK (1) DK2874624T3 (ru)
DO (1) DOP2014000288A (ru)
ES (1) ES2752034T3 (ru)
HR (1) HRP20191730T1 (ru)
HU (1) HUE046427T2 (ru)
IL (1) IL236713B (ru)
LT (1) LT2874624T (ru)
MX (2) MX387668B (ru)
MY (1) MY172561A (ru)
NI (1) NI201400152A (ru)
PH (1) PH12014502716A1 (ru)
PL (1) PL2874624T3 (ru)
PT (1) PT2874624T (ru)
RU (1) RU2643327C2 (ru)
SI (1) SI2874624T1 (ru)
SV (1) SV2014004882A (ru)
UA (1) UA118654C2 (ru)
WO (1) WO2014014363A1 (ru)
ZA (1) ZA201409322B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015014963B1 (pt) * 2012-12-20 2022-04-12 Alleva Animal Health Limited Formulação de suspensão injetável veterinária

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE49770B1 (en) 1979-05-21 1985-12-11 Leo Pharm Prod Ltd 6beta-halopenicillanic acid derivatives
IE51516B1 (en) * 1980-10-06 1987-01-07 Leo Pharm Prod Ltd 1,1-dioxapenicillanoyloxymethyl 6-(d-alpha-amino-alpha-phenylacetamido)penicillanate napsylate
IL64009A (en) 1980-10-31 1984-09-30 Rech Applications Therap Crystalline 1,1-dioxopenicillanoyloxymethyl 6-(d-alpha-amino-alpha-phenylacetamido)penicillanate tosylate hydrates,their production and pharmaceutical compositions containing them
IE51846B1 (en) 1980-11-17 1987-04-15 Leo Pharm Prod Ltd Pharmaceutical preparation for veterinary use and an appliance containing it
EP0115001B1 (de) 1982-12-28 1988-06-15 Bayer Ag Stabile Aminoglykosid-Penicillin-Injektionsformulierungen
US5736151A (en) 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
CH693625A5 (it) * 1999-02-18 2003-11-28 Inpharma Sa Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi.
US20040022815A1 (en) 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
KR20040015622A (ko) 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
US6911441B2 (en) 2002-12-16 2005-06-28 Akzo Nobel N.V. Prolonged release pharmaceutical composition
CN1517090A (zh) * 2003-01-20 2004-08-04 王玉万 含抗菌药物的兽用混悬注射剂或乳剂
US20050143347A1 (en) * 2003-12-22 2005-06-30 Aventis Pharma Deutschland Gmbh Medicinal lipolysis of accumulations of fat
DE102004025324A1 (de) * 2004-05-19 2005-12-08 Boehringer Ingelheim Vetmedica Gmbh Flüssige Zubereitung für die Veterinärmedizin, Verfahren zu deren Herstellung und deren Verwendung
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US8679540B2 (en) * 2006-06-09 2014-03-25 Flamel Technologies Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
AU2008316225B2 (en) * 2007-10-26 2014-06-19 Avivagen Inc. Compositions and methods for enhancing immune response
DK2294012T3 (da) * 2008-05-07 2014-10-06 Salix Pharmaceuticals Ltd Administration af et tarmrensemiddel og et antibiotika til behandlingen af tarmsygdom
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
US20100305500A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
CN101822637A (zh) 2009-12-31 2010-09-08 天津瑞普生物技术股份有限公司 一种含有β-内酰胺类抗生素的混悬注射剂
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
DE102010015143A1 (de) 2010-04-16 2011-10-20 Cts Chemical Industries Ltd. Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon
JP6120834B2 (ja) * 2011-06-23 2017-04-26 バイエル・ニュージーランド・リミテッド 大環状ラクトンおよびレバミゾールを含む抗寄生生物性組成物、ならびに寄生生物感染の処置方法
MX2014007735A (es) 2011-12-23 2014-08-01 Bayer New Zealand Ltd Formulaciones de antibioticos.
DK2819699T3 (da) * 2012-02-27 2019-08-12 Bayer New Zealand Ltd Sammensætninger med kontrolleret frigivelse og fremgangsmåder til anvendelse deraf

Also Published As

Publication number Publication date
MX2014015927A (es) 2015-03-03
HUE046427T2 (hu) 2020-03-30
PT2874624T (pt) 2019-11-04
UA118654C2 (uk) 2019-02-25
US20150174248A1 (en) 2015-06-25
RU2643327C2 (ru) 2018-01-31
LT2874624T (lt) 2019-12-10
ES2752034T3 (es) 2020-04-02
CL2014003423A1 (es) 2015-04-17
KR20150036092A (ko) 2015-04-07
CN104470517B (zh) 2018-12-18
PH12014502716B1 (en) 2015-02-02
HRP20191730T1 (hr) 2019-12-13
DK2874624T3 (da) 2019-11-11
DOP2014000288A (es) 2015-02-15
IL236713B (en) 2018-05-31
EP2874624B1 (en) 2019-08-21
AU2013290826B2 (en) 2018-10-18
CR20140550A (es) 2015-02-05
EP2874624A1 (en) 2015-05-27
MX387668B (es) 2025-03-18
JP2015522608A (ja) 2015-08-06
CN104470517A (zh) 2015-03-25
SV2014004882A (es) 2016-11-11
SI2874624T1 (sl) 2020-02-28
US10376585B2 (en) 2019-08-13
CO7240359A2 (es) 2015-04-17
MY172561A (en) 2019-12-03
CA2875351A1 (en) 2014-01-23
BR112014031083B1 (pt) 2021-06-15
NI201400152A (es) 2015-03-27
BR112014031083A2 (pt) 2017-06-27
KR102113822B1 (ko) 2020-05-22
JP6189437B2 (ja) 2017-08-30
EP2874624B8 (en) 2019-10-02
IL236713A0 (en) 2015-02-26
CA2875351C (en) 2021-08-31
WO2014014363A1 (en) 2014-01-23
AU2013290826A1 (en) 2015-01-15
MX358248B (es) 2018-08-10
PL2874624T3 (pl) 2020-07-27
PH12014502716A1 (en) 2015-02-02
EP2874624A4 (en) 2015-12-02
RU2015105251A (ru) 2016-09-10

Similar Documents

Publication Publication Date Title
SG10201609940RA (en) Compounds and their methods of use
IL252566A0 (en) Pharmacy preparations and methods
EP2834322A4 (en) BIOCHARBON COMPOSITIONS AND METHODS OF USE
SG11201501499SA (en) Multi-functional compositions and methods of use
EP2897639A4 (en) IMPROVED VACCINE COMPOSITIONS AND METHODS OF USE
EP2852397A4 (en) HUWENTOXIN IV VARIANTS AND METHODS OF USE
HUE043820T2 (hu) Liofilizált TAT-NR2B9c készítmény
IL235968A0 (en) Polysaccharide preparations and methods of use
ZA201406267B (en) Controlled release compositions and their methods of use
IL233961A0 (en) The composition of a phytogenic supplement and methods of its use
GB201208315D0 (en) Pharmaceutical methods and compositions
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
ZA201409322B (en) Injectable antibiotic formulations and their methods of use
IL233879A0 (en) Dry powdered dnase i preparations
AU2012901658A0 (en) Compositions and methods of use
GB201207064D0 (en) Pharmaceutical compositions comprising 15-hetre and methods of using the same
AU2012900651A0 (en) Compounds and methods of their use
AU2012900650A0 (en) Compounds and methods of their use